Oppenheimer set a $4.00 target price on ConforMIS (NASDAQ:CFMS) in a research report report published on Thursday morning. The brokerage currently has a buy rating on the medical instruments supplier’s stock. Oppenheimer also issued estimates for ConforMIS’s Q1 2018 earnings at ($0.24) EPS, Q2 2018 earnings at ($0.21) EPS, Q3 2018 earnings at ($0.20) EPS, Q4 2018 earnings at ($0.17) EPS and FY2019 earnings at ($0.68) EPS.

Several other equities research analysts also recently issued reports on the stock. BTIG Research reissued a buy rating and set a $4.00 price objective on shares of ConforMIS in a research report on Wednesday, January 10th. JPMorgan Chase & Co. downgraded shares of ConforMIS from a neutral rating to an underweight rating in a research report on Tuesday, January 2nd. Finally, Zacks Investment Research downgraded shares of ConforMIS from a buy rating to a hold rating in a research report on Tuesday, October 31st. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and three have assigned a buy rating to the company’s stock. The stock has an average rating of Hold and an average target price of $4.88.

Shares of ConforMIS (NASDAQ CFMS) opened at $1.38 on Thursday. ConforMIS has a 12 month low of $1.15 and a 12 month high of $8.61. The company has a quick ratio of 5.38, a current ratio of 6.19 and a debt-to-equity ratio of 0.52. The company has a market cap of $81.23, a P/E ratio of -1.11 and a beta of 1.41.

ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings data on Wednesday, February 7th. The medical instruments supplier reported ($0.27) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.03. ConforMIS had a negative net margin of 68.59% and a negative return on equity of 78.44%. The company had revenue of $20.80 million during the quarter, compared to the consensus estimate of $20.07 million. During the same quarter in the prior year, the firm earned ($0.37) earnings per share. The firm’s revenue was down 4.1% compared to the same quarter last year. equities research analysts forecast that ConforMIS will post -0.86 EPS for the current fiscal year.

In other news, CTO Daniel Steines sold 15,485 shares of the stock in a transaction on Wednesday, November 15th. The shares were sold at an average price of $3.15, for a total transaction of $48,777.75. Following the completion of the sale, the chief technology officer now owns 254,652 shares of the company’s stock, valued at $802,153.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David Cerveny sold 16,392 shares of the stock in a transaction on Wednesday, November 15th. The stock was sold at an average price of $3.17, for a total transaction of $51,962.64. Following the sale, the insider now directly owns 151,408 shares of the company’s stock, valued at approximately $479,963.36. The disclosure for this sale can be found here. Insiders have sold 93,291 shares of company stock valued at $248,077 in the last three months. 9.55% of the stock is owned by insiders.

A number of institutional investors have recently added to or reduced their stakes in the stock. Wells Fargo & Company MN grew its position in ConforMIS by 2.0% in the second quarter. Wells Fargo & Company MN now owns 55,021 shares of the medical instruments supplier’s stock valued at $236,000 after purchasing an additional 1,091 shares in the last quarter. The Manufacturers Life Insurance Company grew its position in ConforMIS by 21.4% in the second quarter. The Manufacturers Life Insurance Company now owns 37,121 shares of the medical instruments supplier’s stock valued at $158,000 after purchasing an additional 6,535 shares in the last quarter. Rhumbline Advisers grew its position in ConforMIS by 21.8% in the second quarter. Rhumbline Advisers now owns 44,782 shares of the medical instruments supplier’s stock valued at $192,000 after purchasing an additional 8,017 shares in the last quarter. State Street Corp grew its position in ConforMIS by 1.5% in the second quarter. State Street Corp now owns 594,583 shares of the medical instruments supplier’s stock valued at $2,550,000 after purchasing an additional 8,693 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in ConforMIS by 31.1% in the second quarter. Alliancebernstein L.P. now owns 40,000 shares of the medical instruments supplier’s stock valued at $172,000 after purchasing an additional 9,500 shares in the last quarter. 35.37% of the stock is owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece was first reported by Watch List News and is owned by of Watch List News. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://www.watchlistnews.com/oppenheimer-reiterates-4-00-price-target-for-conformis-cfms/1859723.html.

About ConforMIS

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Analyst Recommendations for ConforMIS (NASDAQ:CFMS)

Receive News & Ratings for ConforMIS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS and related companies with MarketBeat.com's FREE daily email newsletter.